Print full article

Zoetis earns license for Cytopoint skin therapy

The newly branded therapy, formally known as Canine Atopic Dermatitis Immunotherapeutic, is formulated to target and neutralize interleukin-31 (IL-31)

Suggested Veterinary Products

Apoquel, say hello to your baby brother Cytopoint.

Veterinary drug maker Zoetis Inc. in December received a U.S. Department of Agriculture license for Cytopoint, which the Parsippany, N.J., company described as the first monoclonal antibody (mAb) therapy approved “to help provide sustained control of the clinical signs associated with atopic dermatitis in dogs.”

If the indication sounds familiar, it may be because Cytopoint earned a conditional license in August 2015, when it was known as Canine Atopic Dermatitis Immunotherapeutic. Cytopoint is injected every four to eight weeks.

The newly branded therapy is formulated to target and neutralize interleukin-31 (IL-31). The atopic dermatitis drug Apoquel (oclacitinib tablet) is designed to quickly rid dogs of the urge to itch.

Leave a Comment


Your email address will not be published. Required fields are marked *


Sign-up for your account with Veterinary Practice News. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, a survey now and then, and offers to the veterinarian industry*).

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.